ADME screen

NEW YORK (GenomeWeb News) – Agilent Technologies announced that it and a team of researchers from six organizations are developing models for toxicology testing with a $6 million grant from the National Institutes of Health.

RainDance is partnering with Roche 454 and Ambry in two separate alliances aimed at developing ADME gene screening panels for use on next-generation sequencing instruments.

The partners aim to develop a transporter-based assay system capable of predicting absorption, distribution, metabolism, and excretion of drug candidates.

The lawsuit claims that Invitrogen and CellzDirect are infringing a Celsis patent that relates to processes and methods for producing cryopreserved hepatocytes.

The Seoul-based life sciences firm will provide an array of services to help develop biological assays for cancer and endocrine disorders.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.